FDA approves extension of Eylea HD dosing intervals

The FDA approved an extension of dosing intervals for Eylea HD in patients with diabetic macular edema and wet age-related macular degeneration, Regeneron Pharmaceuticals, Inc. announced.
The approval, which extended the dosing intervals up to every 20 weeks, also includes an update to the Eylea HD (aflibercept 8 mg, Regeneron) label to include 2-year data from “the pivotal” PULSAR and PHOTON trials, according to a press release.
“The potential for needing only two or three Eylea HD injections a year to manage certain retinal diseases is an exciting advance that could benefit

CDC warns of medetomidine in illicit drugs

The CDC issued a health advisory to warn health care professionals, laboratorians, veterinarians and people at risk for overdose about rising reports of medetomidine in the U.S. illicit drug supply.
The agency also warned of severe withdrawal syndrome due to medetomidine exposure.
According to the advisory, medetomidine — also known as “rhino tranq,” “dex” or “mede” — is approved for analgesia and sedation in dogs but not for use in people.
The CDC said that the sedative — first identified in the illegal drug supply in 2021 — has been

K.C. Pharmaceuticals recalls more than 3 million eye drop bottles

Editor’s note: This is a developing news story. Please check back soon for updates.
K.C. Pharmaceuticals is recalling more than 3.1 million bottles of eye drops due to “lack of assurance of sterility,” according to the FDA.
The eight affected products, totaling 3,111,072 individual units, have been distributed throughout the U.S.
It is a class II recall, meaning the drops may cause temporary or reversible adverse effects, or have a low probability of causing severe adverse effects.
The following products have been recalled:

Zenkuda superior to sham in phase 3 diabetic retinopathy study

Zenkuda demonstrated superiority over sham in patients with diabetic retinopathy in the phase 3 GLOW2 study, according to a press release from Kodiak Sciences.
In the confirmatory study, patients with proliferative diabetic retinopathy and mild diabetic macular edema and patients with moderately severe to severe diabetic retinopathy were randomly assigned to receive Zenkuda (tarcocimab tedromer) intravitreal injection (130 patients) or sham injection (125 patients), with dosing at baseline and at weeks 4, 8, 20 and 44. By the end of the study, all patients were on a 6-month dosing interval.
At

Gut-, diet-derived metabolites linked to cognitive impairment

Using six gut- and diet-derived metabolites, a machine learning model had 79% accuracy in classifying adults as having cognitive impairment or being cognitively healthy, according to data published in Gut Microbes.
“Blood-based markers may soon help identify patients at elevated risk long before cognitive impairment can be detected by imaging or clinical tests,” David Vauzour, PhD, HDR, AFHEA, MRSC, associate professor in molecular nutrition at the University of East Anglia’s Norwich Medical School in the U.K., told Healio. “These markers could support early stratification, helping clinicians

Maternal COVID-19 vaccination protects infants for up to 6 months

COVID-19 vaccination during pregnancy protected infants up to 6 months after birth, according to a study published recently in Pediatrics.
The study is part of a larger research project in Scandinavia investigating COVID-19 in pregnancy, according to lead author Helena Niemi Eide, MD, MPH, a doctoral research fellow in the department of community medicine and global health at the University of Oslo in Norway.
“When new vaccines are introduced, it is important to study the consequences for pregnant women and their children, including both safety and effectiveness,” Eide told Healio. “This study

Calcium score predictive of ASCVD risk from elevated Lp(a)

NEW ORLEANS — Lipoprotein(a) levels significantly modified risk for incident atherosclerotic heart disease across individuals’ strata of coronary artery calcium score, a speaker said at the American College of Cardiology Scientific Session.
CAC scoring may help guide risk stratification and preventive treatment decision among individuals with elevated Lp(a), especially for middle-aged men, according to the study, which was simultaneously published in the Journal of the American College of Cardiology.
“Elevated Lp(a) is very common, and with increasing testing, we will identify more individuals

Patients want high-quality care, provider choice, affordability

Click here to read the Cover Story, “Paralympian initiates advocacy for eye care.”
A key factor to generate new patients for an eye care practice is patient word-of-mouth referrals.
To maximize patient advocacy, we must generate patients who are satisfied with their care experience. In addition, happy patients also make for happier practice employees and doctors. Arguably, along with providing high-quality care, generating happy patients satisfied with their care experience is core to our purpose as physicians. To the classical saying “happy spouse, happy house,” we can add “happy patients,

Abrocitinib substantially improved chronic hand eczema

DENVER — Treatment with abrocitinib, an oral JAK1 inhibitor, led to substantial improvements in the signs and symptoms of chronic hand eczema, including skin lesions and pain, according to new data.
Chronic hand eczema (CHE) is defined as eczema that lasts at least 3 months or recurs at least twice a year, Robert Bissonnette, MD, MSc, CEO and medical director of Innovaderm, said during a late-breaking presentation at the American Academy of Dermatology Annual Meeting.
“It’s a very common skin condition,” Bissonnette said. “A recent study conducted in Europe, U.K. and Canada showed that 1 year

Reimbursement for one-stage exchange lags behind two-stage

NEW ORLEANS — Although one-stage exchange may effectively treat periprosthetic joint infection, results presented here showed reimbursement for one-stage exchange lags behind two-stage exchange.
“We advocate for payers to increase one-stage surgical fees to align incentives with current evidence and believe this can be done while preserving the cost benefit one stage has been shown to offer,” Enrico Forlenza, MD, of Rush University Medical Center, said in his presentation at the American Academy of Orthopaedic Surgeons Annual Meeting.
To examine the differences in